Impact of Regional Income and Insurance Status on Survival of Multiple Myeloma Patients: Autologous Stem Cell Transplant as an Equalizer

Patients with Multiple Myeloma (MM) are enjoying significant improvement in overall survival as the result of advent of novel anti-myeloma agent that replace traditional chemotherapy, in addition to the increased use of transplant. The prices of novel agents, especially oral ones, have been rapidly escalating and there are well-described issues with affordability (Shih et al. JCO 2017). We therefore hypothesized that insurance status influences MM patients (pts) survival. National Cancer Database (NCDB), covering 70% of MM patient nationwide was utilized.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Kamal Chamoun, Marcos De Lima, Pingfu Fu, Paolo Fabrizio Caimi, Shufen Cao, Stan Gerson, Kirsten M. Boughan, Molly Gallogly, Leland Metheny, Ehsan Malek Source Type: research